NSAIDs in CV System

Eicosanoids Overview

  • Eicosanoids: A diverse family of lipid mediators crucial for physiology and disease.
    • Includes prostanoids, derived from arachidonic acid via cyclooxygenase (COX).
  • Cyclooxygenase (COX): Two isoforms, COX-1 and COX-2.
    • COX-1: Constitutively expressed in many cell types.
    • COX-2: Inducibly expressed, primarily during inflammation and cancer, target for NSAIDs.

Historical Context

  • Prostacyclin (PGI2): Discovered by Sir John Vane in 1976, a key cardiovascular protective pathway.
    • Functions include inhibition of platelet aggregation and vasodilation.
  • COX-1 and COX-2's relationship with prostacyclin led to Vane receiving a share in the 1982 Nobel Prize for Physiology and Medicine.

Importance of Eicosanoids and COX in Health and Disease

  • COX plays a role in various health aspects; significant in inflammation, pain, and cardiovascular functions.
  • Systematic research shows 56,082 publications on COX, with 9,006 linked to vascular studies, emphasizing its cardiovascular functions.

Eicosanoids Classification

  • Eicosanoids Categories:
    • Leukotrienes
    • Lipoxins
    • Hydroxyeicosatetraenoic acids (HETEs)
    • Hydroperoxyeicosatetraenoic acids (HpETEs)
    • Epoxyeicosatrienoic acids (EETs)
    • Dihydroxyeicosatrienoic acids (DHETs)
    • Isoprostanes
    • Resolvins
    • Prostanoids: Key in cardiovascular activity, notably prostacyclin.

Pathways of Prostanoid Synthesis

  • Phospholipases (PLA2): Release arachidonic acid from membrane phospholipids.
    • Major isoforms: cPLA2, iPLA2, sPLA2.
    • cPLA2 is crucial for arachidonic acid liberation in blood vessels.
  • Cyclooxygenase (COX): Converts arachidonic acid into prostanoids.
    • Two Enzymic Steps:
    1. Oxidation of arachidonic acid to PGG2.
    2. Conversion to PGH2.
    3. PGH2 is further converted to various prostanoids (e.g., PGI2, thromboxanes (TXA2)).

COX Enzyme Characteristics

  • COX-1: Ubiquitous; constitutively expressed across tissues.
  • COX-2: Induced at inflammation sites; previously thought only to be an inducible form but discovered to be constitutively expressed in key regions (e.g., kidneys, brain).

Cardiovascular Protection by COX-2

  • Role of COX-2:
    • Acts as a protective enzyme against cardiovascular disease.
    • Essential for producing prostacyclin in the vascular endothelium, promoting vascular health.
  • NSAIDs: Non-steroidal anti-inflammatory drugs targeting COX-2 can unintentionally inhibit protective COX-2 activity, causing cardiovascular side effects.
    • Issues associated with traditional NSAIDs (e.g., ibuprofen, naproxen) showed similar cardiovascular risks as selective COX-2 drugs (e.g., celecoxib, rofecoxib).

Cardiovascular Side Effects of NSAIDs

  • Epidemiological studies indicate increased risk of cardiovascular events in NSAID users (e.g., hypertension, heart attacks).
    • Risk can present after just 2 weeks of regular use.
    • Estimates suggest 30,000-50,000 NSAID-attributable cardiovascular events annually in the UK.
  • Special case of Aspirin: Reduces cardiovascular risks; it selectively targets TXA2 release from platelets, offering protection.

Mechanisms Linking COX-2 with Vascular Health

  • Prostacyclin Synthase: Facilitates the production of prostacyclin in blood vessels, indicated by the presence of both COX and prostacyclin synthase in endothelial tissues.
  • eNOS Pathway: COX-2-derived prostacyclin enhances endothelial nitric oxide synthase (eNOS) function, which is critical for vascular health.
    • Inhibition leads to increased levels of ADMA (asymmetric dimethylarginine), an endogenous inhibitor of eNOS, exacerbating hypertension and thrombosis.

Genetic Considerations in NSAID Cardiovascular Toxicity

  • Genetic studies propose specific loci are linked to NSAID-induced cardiovascular toxicity.
    • Examined in the Adenoma Prevention with Celecoxib trial.

Summary and Future Directions

  • Focus on prostacyclin's therapeutic potential in cardiovascular diseases through its complex signaling pathways.
  • Understanding mechanisms of NSAIDs' cardiovascular side effects is crucial for patient safety and drug development.
  • Genetic biomarkers and precision medicine approaches may enhance risk assessment and management in NSAID therapy.

Acknowledgments and Conflicts of Interest

  • Acknowledgment of funding and financial disclosures related to research supporting prostacyclin and NSAIDs research.